Zai LabZLAB -0.21%64 3-Year EBITDA Growth Rate is 31.70% as of Mar. 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.26 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 1,136 Biotechnology companies, Zai Lab ranks better than 69.37% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 31.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 20.10% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -14.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zai Lab was 31.70% per year. The lowest was -99.20% per year. And the median was -14.75% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Zai Lab 3-Year EBITDA Growth Rate Related Terms
ZLAB vs STOK, ADMA, VRDN: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Zai Lab's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Zai Lab's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 31.70% mean?
Zai Lab (ZLAB) has a 3-Year EBITDA Growth Rate of 31.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zai Lab and its competitors. According to the industry distribution chart, Zai Lab ranks #348 out of 1136 companies in the Biotechnology industry, placing it in the top 30.6%.
Is Zai Lab's 3-Year EBITDA Growth Rate too high?
Zai Lab's current 3-Year EBITDA Growth Rate is 31.70%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Zai Lab's value of 31.70% is 113.5% above this industry median. Based on the distribution chart, Zai Lab ranks #348 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's 3-Year EBITDA Growth Rate compare to STOK and ADMA?
According to the Biotechnology industry distribution chart, Zai Lab ranks #348 out of 1136 companies for 3-Year EBITDA Growth Rate. This puts Zai Lab in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Zai Lab's value of 31.70% is 113.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,136 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zai Lab's current 3-Year EBITDA Growth Rate of 31.70% is 113.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zai Lab and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current 3-Year EBITDA Growth Rate is 31.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.26, compared to a current price of $19.14 — trading 36.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 31.70% and 113.5% above the Biotechnology industry median of 14.85. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Zai Lab (ZLAB), the current 3-Year EBITDA Growth Rate is 31.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $19.14 is trading 36.8% below its estimated GF Value™ of $30.26.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for ZLAB:
3-Year EBITDA Growth Rate: 31.70%
GF Value™: $30.26 vs. price of $19.14 (36.8% below fair value)
Industry Position: 113.5% above the Biotechnology median (#348 of 1136)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score
Get the complete analysis for ZLAB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 